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the results of a controversial study 
should overrule the recommendations 
from a comprehensive evidence­based 
guideline that was based on eight ran­
domised controlled trials.
A more balanced recommendation 
would have been appropriate, since 
withholding patients a potentially 
effective treatment, integrated into a 
multidisciplinary approach, cannot be 
considered as good clinical practice.
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Authors’ reply
Christelle Nguyen and colleagues, 
Tim Germon and colleagues, and 
Kosmas I Paraskevas argue that we 
did not pay sufficient attention to 
the specific nociceptive causes of 
low back pain in our Lancet Series on 
low back pain. We were quite explicit 
that low back pain is a symptom 
not a disease and can result from 
several different known or unknown 
abnormalities or diseases.1 When it is 
possible to define additional specific 
nociceptive causes for low back pain 
with effective treatments then we will 
be able to address this major health 
issue, as Germon and colleagues 
suggest. There is insufficient evidence 
to support the existence of any such 
specific causes of low back pain beyond 
those we mentioned in the Series—
ie, malignancy, fracture, infection, 
or inflammatory disorders such as 
ankylosing spondylitis.1 Nguyen and 
colleagues draw attention to their work 
on intradiscal glucocorticoid injections 
to support their case for including 
discopathy as a specified nociceptive 
pain source. In a highly selected patient 
group the authors found a reduction in 
pain but not disability at 1 month and 
no long­term benefits. We agree with 
their conclusions, that the efficacy of 
glucocorticoid intradiscal injection as a 
possible treatment for chronic low back 
pain associated with active discopathy 
is questionable, given the lack of long­
term benefit.2 We agree with Paraskevas 
on the importance of recognising 
ruptured aortic aneurysm, and indeed 
other intra­abdominal emergencies 
and malignancies, as causes of acute 
low back pain. These conditions are, 
however, uncommon causes of low 
back pain, and poor explanations for 
long­term low back pain and disability.
Until recently, we might have agreed 
with Damian M Bailey and colleagues 
that promotion of exercise might 
help reduce cognitive decline in older 
people. However, there are now good 
quality prospective data to show that, 
although physical activity declines in 
the years preceding diagnosis, there is 
no neuroprotective effect of physical 
activity on cognitive function.3 
Furthermore, a randomised controlled 
trial of exercise for people with mild 
to moderate dementia found exercise 
training had a detrimental effect on 
cognitive function.4 Although there 
might be many reasons to promote 
physical activity and exercise, the 
prevention of dementia appears not to 
be one of them.
Jan Van Zundert and colleagues 
challenge our portrayal of epidural 
injections and radiofrequency de­
nervation. The authors dispute our 
statement that epidural glucocorticoid 
injection for herniated disc with 
radiculopathy has only a small short­
term effect.5 However, the review 
they cite in support of their argument 
actually concluded: “the available 
evidence suggests that epidural 
corticosteroid injections offer only 
short­term relief of leg pain and 
disability for patients with sciatica. 
The small size of the treatment effects, 
however, raises questions about the 
clinical utility of this procedure in the 
target population”.6 The authors also 
question our summary of the place 
of radiofrequency denervation for 
chronic low back pain. Although the 
National Institute for Health and Care 
Excellence7 recommended use of the 
treatment for patients with moderate 
to severe chronic low back pain who 
have had insufficient improvement 
despite comprehensive conservative 
management including a combined 
physical and psychological programme, 
they also listed radiofrequency 
denervation as one of their five future 
research recommendations because 
of the absence of conclusive evidence 
for effectiveness. The results of a 2015 
Cochrane review8 examining the 
same research showed that there was 
no high­quality evidence to suggest 
that radiofrequency reduced pain or 
improved function in people with 
chronic low back pain. The UK National 
Institute for Health Research Health 
Technology Assessment Pro gramme 
is seeking to commission a new trial in 
the UK comparing this procedure versus 
sham radiofrequency denervation. The 
evidence from the Dutch Mint trials 
suggested that radiofrequency did not 
provide greater benefit than an exercise 
programme.9 We acknowledge that 
the Mint trials have been controversial. 
The same level of critical appraisal also 
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that appear to support use of the 
procedure. We therefore are of the firm, 
and balanced, view that radiofrequency 
denervation should be withheld from 
patients unless within the context of 
a high quality research trial that can 
reduce the uncertainty about value of 
the procedure.
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this guideline,1 reports a pooled relative 
risk (RR) of 0·62 with a 95% CI of 
0·23–1·26.4 This point estimate includes 
trials at both high and low risk of 
bias, and does not include a recent 
RCT of 197 patients.5 As part of the 
2017 Society of Critical Care Medicine 
(SCCM) and European Society of Critical 
Care Medicine (ESICM) Corticosteroid 
Guideline Task Force, we updated the 
evidence summary examining the 
efficacy of corticosteroids in acute 
respiratory distress syndrome. In 
an updated systematic review and 
meta­analysis,2 specifically designed 
to support this guideline effort, we 
identified nine RCTs (as compared 
with the five identified by the 2008 
systematic review). Five of these RCTs 
were rated as having a low risk of 
bias, and subsequent meta­analysis of 
these five studies showed a pooled RR 
estimate of 0·76 (95% CI 0·58–0·99) 
for hospital mortality when using 
corticosteroids. This estimate includes 
only studies with low risk of bias and 
includes all recent trial data (up until 
the time of publication). The net effect, 
compared with the 2008 review,2 
is a decrease in imprecision (upper 
end of the CI now excludes harm), 
and a decrease in concerns related 
to risk of bias producing moderate­
quality evidence of benefit with 
corticosteroids.
Armed with this higher­certainty 
evidence, and combined with our 
updated review that showed an 
increase in mechanical ventilator­
free days with corticosteroids 
(mean difference 7·06 days fewer, 
95% CI 3·19–10·93, high certainty 
evidence), the 2017 SCCM and ESICM 
guideline panel made a conditional 
recommendation for corticosteroids in 
acute respiratory distress syndrome.6 
We suggest that the FICM and ICS 
consider updating their guideline 
development processes. Although there 
are time and resource implications 
for societies contemplating updating 
systematic reviews, the investment is 
necessary if the goal is to provide the 
most up­to­date and comprehensive 
Discrepancies in guidelines 
for acute respiratory 
distress syndrome
In July, 2018, the Faculty of Intensive 
Care Medicine (FICM) and the Intensive 
Care Society (ICS) released their 
guidelines on the management of acute 
respiratory distress syndrome.1 These 
guidelines used GRADE methodology 
to develop evidence based recom­
mendations for the management of 
acute res piratory distress syndrome in 
adult patients in intensive care. Overall, 
the guideline provides useful guidance 
to stakeholders.
Our main concern with the guidelines1 
is that the evidence summaries 
rely on previously completed sys­
tematic reviews and meta­analyses, 
rather than performing an updated 
analysis specifically for this guideline 
effort. The result is that many of 
the recommendations are based on 
evidence summaries that are outdated, 
not entirely relevant, or do not include 
the most recent trial data. This greatly 
lowers the trustworthiness of the 
recommendations. For example, the 
evidence profile addressing corti­
costeroids in acute respiratory distress 
syndrome synthesises the results of 
three meta­analyses published in 2008,2 
2009,3 and 2014.4 Two of these meta­
analyses2,4 incorporate randomised 
controlled trials (RCTs) from the 
1980s that investigated short­term 
(24–48 h) and large­dose corticosteroids 
(up to 120 mg/kg methylprednisolone 
equivalent), an intervention that is 
obsolete and discredited by the present 
pathophysiological understanding of 
acute respiratory distress syndrome. 
Using this evidence summary that 
was judged to be very low quality, the 
FICM–ICS guideline panel did not feel 
confident in making a recommendation 
for or against corticosteroids in acute 
respiratory distress syndrome and 
instead made a research recom­
mendation.
Hospital mortality, extracted from 
the 2008 meta­analysis and used in 
See Online for appendix
